Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04330716 · ClinicalTrials.gov registry record · NA
Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 269
- Enrollment target
NCT04330716: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT04330716 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 269 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04330716, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 269 participants
- Enrollment target
Study Summary
This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.
Primary Outcome
Measurement of genetic testing uptake in breast, ovarian, pancreatic, and prostate cancer patients randomized to pre-genetic test (pre-test) in-person counseling with a genetic counselor per standard of care or video education.This comparison will use a two-sided Fisher exact test
Interventions
- BEHAVIORAL Educational Video
- BEHAVIORAL Standard Genetic Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
What the finished NCT04330716 record still lists
NCT04330716 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Educational Video is the first listed.
NCT04330716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04330716 about?
NCT04330716 is a clinical study titled "Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers". This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.
What is the current status of trial NCT04330716?
This trial is currently completed. It is a NA study. The enrollment target is 269 participants. The study started on 2020-12-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04330716?
The interventions under investigation include: Educational Video (BEHAVIORAL), Standard Genetic Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04330716?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04330716's enrollment target sits among peer trials
269 392nd of 2000 higher than 1,609 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI